Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.

Observations of inflammation and thrombotic events in the lung as a consequence of SARS-CoV-2 infection led to the use of nebulised heparin in the treatment of COVID-19 with a recent meta trial conducted across six countries demonstrating a highly significant reduction in mortality and in reducing the need for ventilation [ 13 ].

also in 132,142 other papers